Karyopharm Therapeutics
KPTI
KPTI
113 hedge funds and large institutions have $113M invested in Karyopharm Therapeutics in 2024 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 36 increasing their positions, 31 reducing their positions, and 22 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
113
Holders Change
-4
Holders Change %
-3.42%
% of All Funds
1.64%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
20
Increased
36
Reduced
31
Closed
22
Calls
$330K
Puts
$321K
Net Calls
+$9K
Net Calls Change
-$421K
Top Buyers
| 1 |
EP
Eversept Partners
New York
|
+$7.57M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$2.77M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$1.01M |
| 4 |
D.E. Shaw & Co
New York
|
+$522K |
| 5 |
State Street
Boston,
Massachusetts
|
+$350K |
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$2.11M |
| 2 |
Renaissance Technologies
New York
|
-$1.6M |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$1.57M |
| 4 |
BlackRock
New York
|
-$942K |
| 5 |
TC
Tejara Capital
London,
United Kingdom
|
-$892K |
